Division of Orthopaedic Surgery, Department of Surgery, University of Toronto, St. Michael's Hospital, Suite 800, 55 Queen Street East, Toronto, Ontario, M5C 1R6, Canada.
Injury. 2009 Dec;40 Suppl 3:S27-31. doi: 10.1016/S0020-1383(09)70008-7.
The management of open fractures continues to be complicated by high rates of treatment failure and significant patient disability and dissatisfaction. The use of bone morphogenetic proteins (BMPs) in the treatment of open fractures has been assessed by a number of different clinical trials, both in the acute management of open fractures and in the delayed reconstruction of bone defects secondary to open fracture. This review describes the scientific basis for the use of BMPs in open fractures, reviews the current evidence for their use in open fractures, provides grades of recommendation for the different uses of BMPs in open fractures, and identifies important areas for additional research.
开放性骨折的治疗仍然存在治疗失败率高、患者残疾和不满意的问题。许多不同的临床试验评估了骨形态发生蛋白（BMPs）在开放性骨折治疗中的应用，包括急性开放性骨折处理和开放性骨折引起的骨缺损的延迟重建。本文描述了 BMPs 在开放性骨折中的应用的科学依据，回顾了其在开放性骨折中的应用的现有证据，为开放性骨折中 BMPs 的不同用途提供了推荐等级，并确定了需要进一步研究的重要领域。
